Patents by Inventor Edward M. Rudnic

Edward M. Rudnic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190358687
    Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Marcus Schestopol, Donald Treacy, Edward M. Rudnic, Beth A. Burnside, John W. Holaday
  • Publication number: 20180001357
    Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 4, 2018
    Applicant: DisposeRx, Inc.
    Inventors: MARCUS SCHESTOPOL, DONALD TREACY, EDWARD M. RUDNIC, BETH A. BURNSIDE, JOHN W. HOLADAY
  • Patent number: 8889187
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 18, 2014
    Assignee: Shionogi Inc.
    Inventors: Edward M Rudnic, James D Isbister, Donald J Treacy, Jr., Sandra E Wassink
  • Publication number: 20140187842
    Abstract: Device for the neutralization and disposal of unused human or animal pharmaceutical medicament. The device comprises a disposal device material that contains one or more disposal device agents. The disposal device material may also contain additional components to promote mixing, or neutralization of the active agent of the medicament. The disposal device material can be in the form of pellets, beads, beadlets, granules, or the like, and can be incorporated into a disposal device reservoir. The disposal device can be dispensed with a medicament, and the device can be used when the patient has finished using the medicament and there is material left over for disposal.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicant: QRxPharma Ltd.
    Inventors: John W. Holaday, Edward M. Rudnic, Beth A. Burnside, Marcus Schestopol, Donald Treacy, Michael Vachon, Sean Higgins, Gary W. Pace
  • Publication number: 20140183070
    Abstract: A device for the neutralization and disposal of unused medicaments, such as drugs or medications. The device generally comprises a means of storing disposal device material, which can render medicaments unusable, and a means of exposing the disposal device material to the medicaments when they are no longer in use. The device may be a medicament container comprising a reservoir to store the disposal device material, and a means to expose the disposal device material to the medicaments. Alternatively, the device may be a medicament closure or lid for use with a medicament container, in which the closure comprises a reservoir for storing the disposal device material and a means to expose the disposal device material to the medicaments.
    Type: Application
    Filed: August 2, 2013
    Publication date: July 3, 2014
    Applicant: QRxPharma Ltd.
    Inventors: John W. Holaday, Edward M. Rudnic, Beth A. Burnside, Donald Treacy, Marcus Schestopol, Kristin Benokraitis, Ed Browka, Jessie Delgado, David Foshee
  • Publication number: 20130022646
    Abstract: Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.
    Type: Application
    Filed: April 9, 2012
    Publication date: January 24, 2013
    Inventors: Edward M. Rudnic, Michael Vachon, Gary W. Pace
  • Publication number: 20120321674
    Abstract: Abuse resistant pharmaceutical formulations are provided that contain one or more abusable drugs and one or more abuse deterrent components. The abuse deterrent component(s) prevent the abusable drug(s) from being removed/extracted to an appreciable extent and/or rate. The abuse deterrent component(s) may be in the form of pellets, beads, beadlets, granules, powders, or the like, and may comprise a core that contains a material that is both hydrophilic and hydrophobic, and optionally a pH-dependent coating.
    Type: Application
    Filed: February 18, 2012
    Publication date: December 20, 2012
    Inventors: Michael Vachon, Edward M. RUDNIC
  • Publication number: 20120321716
    Abstract: Abuse resistant pharmaceutical formulations are provided that contain one or more abusable drugs and one or more abuse deterrent components. The abuse deterrent component(s) prevent the abusable drug(s) from being removed/extracted to an appreciable extent and/or rate. The abuse deterrent component(s) may be in the form of pellets, beads, beadlets, granules, powders, or the like, and may comprise a core that contains a material that is both hydrophilic and hydrophobic, and optionally a pH-dependent coating.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 20, 2012
    Inventors: Michael VACHON, Edward M. RUDNIC
  • Patent number: 8303988
    Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: November 6, 2012
    Assignee: Shionogi Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Publication number: 20120035121
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, JR., Sandra E. Wassink
  • Publication number: 20110195989
    Abstract: Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.
    Type: Application
    Filed: February 9, 2011
    Publication date: August 11, 2011
    Inventors: Edward M. Rudnic, Michael Vachon, Gary W. Pace, Joseph Berry, Felix de la Iglesia
  • Publication number: 20110065718
    Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 17, 2011
    Applicant: Victory Pharma, Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, JR., Sandra E. Wassink
  • Publication number: 20100120896
    Abstract: Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant Staphylococcus aureus, or “MRSA,” the products comprising: a combination of at least two different antibiotics, wherein one of the at least two different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics and wherein one of the at least two different antibiotics is selected from the group consisting of Elongation Factor G (EF-G) Inhibiting antibiotics (alternatively any or all of the aforementioned RNA-Polymerase Inhibiting antibiotics and Elongation Factor G (EF-G) Inhibiting antibiotics may be in the form of analogues, derivatives, polymorphs, metabolites, pro-drugs, salts, and/or hydrates of any of the foregoing); optionally in further combination with a resistance inhibitor, preferably a LexA protease cleavage inhibitor.
    Type: Application
    Filed: July 1, 2009
    Publication date: May 13, 2010
    Inventors: Sanna Sander, Henry H. Flanner, Beth A. Burnside, Donald Treacy, Edward M. Rudnic
  • Publication number: 20100016333
    Abstract: Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant Staphylococcus aureus, or “MRSA,” the products comprising: a combination of at least three different antibiotics, wherein one of the at least three different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics or Phenazine antibiotics, wherein one of the at least three different antibiotics is selected from the group consisting of Dihydropteroate Synthase Inhibiting antibiotics, and wherein one of the at least three different antibiotics is selected from the group consisting of Dihydrofolate Reductase Inhibiting antibiotics (alternatively any or all of the aforementioned RNA-Polymerase Inhibiting antibiotics, Dihydropteroate Synthase Inhibiting antibiotics, and Dihydrofolate Reductase Inhibiting antibiotics may be in the form of analogues, derivatives, polymorphs, metabolites, pro-drugs, salts, and/or hydrates of any of the foregoing); optionally in further combination with a resistance inhib
    Type: Application
    Filed: August 7, 2007
    Publication date: January 21, 2010
    Inventors: Henry H. Flanner, Donald Treacy, Sanna Tolle-Sander, Beth A. Burnside, Edward M. Rudnic
  • Patent number: 7282221
    Abstract: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: October 16, 2007
    Assignee: Middlebrook Pharmaceuticals, Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7157095
    Abstract: An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-fungal from the product.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 2, 2007
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7122204
    Abstract: Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. In a preferred embodiment, release from the second, third and fourth dosage forms is initiated after the component released from the immediately previous form reaches Cmax.
    Type: Grant
    Filed: April 21, 2003
    Date of Patent: October 17, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventor: Edward M. Rudnic
  • Patent number: 7108859
    Abstract: An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antineoplastic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 21, 2002
    Date of Patent: September 19, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: RE41148
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: February 23, 2010
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Edward M. Rudnic, Charlotte M. McGuinness
  • Patent number: RE42096
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: February 1, 2011
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Rong-Kun Chang, Donald J. Treacy, Charlotte M. McGuiness, Edward M. Rudnic